Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{157192,
        author = {Mohammed Sufiyan and Bhavana Patil and Zahid Anwer  and Nazeer Ahmed and Saeed Ahmed},
        title = {A REVIEW ON GOUT},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {6},
        pages = {271-280},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=157192},
        abstract = {The inflammation caused by urate crystals in the joint leads to gout, a common form of inflammatory arthritis. With arthritis as a side effect of this pathological accumulation, gout is now understood to be a disease predominantly caused by urate overload. Numerous significant co-morbidities, such as diabetes, obesity, chronic renal disease, and cardiovascular disease, are linked to it. Everywhere in the world, gout is becoming more common. The understanding of the genetic causes of both hyperuricemia and gout has advanced considerably. It has been determined that specific foods, alcohol, and several drugs are environmental risk factors for gout. But there isn't much proof that reducing these environmental dangers helps people with gout. First, nonsteroidal anti-inflammatories, corticosteroids, colchicine, or interleukin-1 inhibitors are used to treat inflammatory arthritis. The second method of treating gout involves these same drugs. Urate reduction is the second and most crucial method, with a target of 0.36 mmol/L (6 mg/dL) or maybe lower in those with tophi (collections of crystalline urate subcutaneously). In addition to reducing urate, adequate and extended gout flare prevention is necessary to stop the onset of acute flares. The number of available treatments may be greatly increased by the discovery of newer urate-reducing drugs. As medication adherence is low in chronic diseases in general, but especially in gout, patient education about the significance of lifelong urate-lowering therapy and prophylaxis of acute attacks is essential to the effectiveness of treatment.},
        keywords = {},
        month = {},
        }